HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Summary Full Text (PDF) Expanded Tables Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Minneman, K. P. Search for Related Content PubMed PubMed Citation Articles by Minneman, K. P.

Splice Variants of GPCRs

Department of Pharmacology Emory University Medical School Atlanta, GA 30322

Correspondence: E-mail kminneman{at}pharm.emory.edu; fax (404) 727-0365

Each of the cultured human cells shown above expresses the dopamine D₃ receptor, a G protein–coupled receptor, that has been manipulated so as to fluoresce red. Some of the cells additionally express a truncated variant of the D₃ receptor (green) that prevents trafficking of both variants to the plasma membrane and that has been associated with schizophrenia. As discussed in the accompanying article, other GPCRs are subject to less drastic forms of splicing that may play important roles in their localization, trafficking, and signaling.

	ABSTRACT

TOP Abstract INTRODUCTION GPCR GENESTRUCTURE AND SPLICE... FUNCTIONAL DIFFERENCES BETWEEN... LOCALIZATION PROTEIN-PROTEIN INTERACTIONS... DIMERIZATION CONCLUSIONS REFERENCES

 
Gprotein–coupled receptors (GPCRs) are encoded by a vast gene superfamily, reflecting the large number of ligands that must be specifically recognized at any given cell surface. The discovery that the variety of GPCRs is further expanded through the generation of splice variants was therefore somewhat surprising. Studies of the functional consequences of alternative splicing have focused on ligand binding, signaling, constitutive activity, and downregulation. However, GPCRs also appear to interact directly with many other intracellular proteins in addition to G proteins. Intriguingly, the domains involved in these interactions are the predominant sites of variation arising through splicing.

	INTRODUCTION

TOP Abstract INTRODUCTION GPCR GENESTRUCTURE AND SPLICE... FUNCTIONAL DIFFERENCES BETWEEN... LOCALIZATION PROTEIN-PROTEIN INTERACTIONS... DIMERIZATION CONCLUSIONS REFERENCES

 
G protein–coupled receptors (GPCRs) and ligand-gated channels are two important classes of receptors that help define cellular responsiveness to extracellular signals. GPCRs are structurally much simpler than the multimeric ligand-gated channels. It is believed that each GPCR contains a single binding site for its ligand, whereas ligand-gated channels manifest multiple ligand binding sites. Finally, splice variants of ligand-gated channels are common, whereas each GPCR is far more likely to be the single product of its gene. These qualities have tended to make GPCRs, one of the largest human protein families, attractive targets for drug development.

Recent studies, however, suggest that GPCRs may be more complex than previously thought. Evidence is now very strong that GPCRs: i) sometimes arise through alternative splicing; ii) may associate to form homo- or heterodimers within the cell membrane; and iii) can interact directly with other proteins in macromolecular complexes. These new perspectives have had a major impact on our understanding of GPCR pharmacology. In this article, I discuss splice variants of GPCRs and their possible functional significance, a topic recently reviewed by Kilpatrick et al. (1).

	GPCR GENESTRUCTURE AND SPLICE VARIATION

TOP Abstract INTRODUCTION GPCR GENESTRUCTURE AND SPLICE... FUNCTIONAL DIFFERENCES BETWEEN... LOCALIZATION PROTEIN-PROTEIN INTERACTIONS... DIMERIZATION CONCLUSIONS REFERENCES

 
Molecular cloning of GPCRs in the 1980s led to the realization that their genes have unusual structures. Although less than five percent of human genes lack introns in their protein-coding regions, most mammalian GPCRs (>90%) are intron-less (2). This finding led to the widespread use of genomic libraries for the cloning of additional of GPCRs, so that the possibility of alternative gene splicing was generally ignored. However, splice variants of the rat D₂ dopamine receptor were first reported in 1989 (3), and other GPCR genes have since been found to contain introns in their open reading frames (ORFs).

It is now clear that the genes that encode GPCRs are structurally heterogeneous. As Table 1 shows, however, an increasingly complex genomic structure does not correlate with the number of known splice variants. Although most GPCR genes have no introns in their ORFs, others (e.g., rhodopsin) have multiple introns and yet still appear to evade alternative splicing. Some GPCR genes, like that for the D₂ dopamine receptor, have many introns but yield few splice variants, and others, such as that for _1A-adrenergic receptors, have one intron in their primary ORF but yield multiple splice variants. At the extreme, the GABA_B-R₁ (-aminobutyric acid type B receptor 1) gene has twenty introns in its ORF, with only two splice variants reported to date. Further comparison of GPCR genes must remain limited, because there are undoubtedly GPCR splice variants not yet identified. However, many GPCRs have been examined extensively and identification of large numbers of additional splice variants is unlikely.

Splice variants are usually identified by use of the reverse transcriptase–polymerase chain reaction (RT-PCR), or by parallel sequencing of multiple cDNA clones. Tissue distribution of splice variants is often supported by analysis of RNA (usually, in situ hybridization); however, their biological significance can be difficult to determine. Selective antibodies are not usually available, and the heavy reliance on PCR techniques and sequencing can complicate the interpretation of functional relevance. Premature stop codons that would produce proteins lacking one or more transmembrane domains have been reported for several GPCRs (1); however, it is not yet clear whether these truncated proteins are expressed, and they are not considered below. This review focuses only on splice variants of human origin that have been reported by at least two laboratories, or which have been confirmed by at least two methods. These criteria substantially reduce the number of splice variants considered (1) but increase the likelihood of functional relevance. The resulting survey shows that human GPCR splice variants cluster into three main groups (Figure 1): those with variation in the intracellular C-terminal tail; those varying in the third intracellular (i3) loop; and those that vary in the extracellular N terminus. For reasons of space, the few splice variants that have been reported in extracellular and other intracellular loops (1) are not discussed here.

View larger version (35K): [in this window] [in a new window]   Figure 1. Schematic simplification of the GPCR structure and summary of three classes of human GPCR splice variants. The seven transmembrane domains are shown as blue cylinders; the remaining canonical polypeptide sequence is shown as colored string: extracellular loops (e1, e2, and e3), and two intracellular loops (i1 and i2) are shown in blue; the N-terminal sequence is green; intracellular loop i3 is red; and the C-terminal sequence is purple. Alternative splice variants, including those that represent alternative N and C termini, are indicated by the pod-like expansions superimposed upon the string. Numbers in parentheses next to receptor names indicate how many splice variants exist in addition to the first receptor cDNA sequence cloned. Human sequences verified by two independent labs or approaches are included. References for each of the splice variants are available in the online version of this article.

SPLICE VARIANTS OF THE THIRD INTRACELLULAR LOOP
Seven variants pertain to alteration of the third intracellular (i3) loop, representing four receptors (Figure 1), and arise through variable insertion of coding exons. The dopamine D₂ receptor, the first GPCR for which a splice variant was reported, exists in "short" and "long" forms that differ by twenty-nine residues in the i3 loop. The PACAP (pituitary adenylate cyclase activating polypeptide) receptor may be the most interesting example in this class, where variable insertion of two alternative 28-residue segments in the i3 loop results in four separate human isoforms. Similar splice variants of histamine H₃ and cholecystokinin B receptors have also been reported.

SPLICE VARIANTS OF THE N TERMINUS
Five variants of three receptors are confirmed that represent variation in the extracellular N terminus (Figure 1). These are formed by exon skipping, resulting in either a truncated terminus, or a short deletion within the domain. Human GABA_B-R₁ receptors belongs to this group, with GABA_B-R_1b receptors having a truncated N terminus and GABA_B-R_1c receptors having a shorter deletion in this region. Similar isoforms have been reported for the CRFR2 (corticotropin-releasing factor receptor type 2) receptor and the PACAP receptor.

	FUNCTIONAL DIFFERENCES BETWEEN SPLICE VARIANTS

TOP Abstract INTRODUCTION GPCR GENESTRUCTURE AND SPLICE... FUNCTIONAL DIFFERENCES BETWEEN... LOCALIZATION PROTEIN-PROTEIN INTERACTIONS... DIMERIZATION CONCLUSIONS REFERENCES

 
Because there are often many closely related GPCRs for a particular ligand, the role of additional splice variants is unclear. For example, there are three ₁-adrenergic receptor subtypes among the nine adrenergic receptors. These closely related subtypes respond to the same transmitter and activate the same signals (7), and so the existence of three additional splice variants of the _1A subtype is puzzling (8, 9). However, the structural regions where the splice variations occur have led to some ideas about their function. The i3 loop and C-terminal tail are often important in G protein coupling, whereas C-terminal phosphorylation plays an important role in desensitization. Thus, G protein coupling and desensitization of GPCRs alternatively spliced in these regions have been carefully compared. The N terminus is often involved in amino acid and polypeptide binding, and N-terminal splice variants have been proposed to influence binding specificity. In addition, recent findings about interactions of GPCRs with other proteins may provide new insights into the functional roles of splice variants.

COUPLING EFFICIENCY
G protein activation is the major function of GPCRs, and the efficiency and specificity of coupling of splice variants is worthy of particular attention. Coupling differences have been reported for several known splice variants, particularly for those differing in intracellular domains. When rat PACAP receptor isoforms with alternatively spliced i3 loops were first identified, they were shown to differentially couple to adenylate cyclase and phospholipase C (10). Similarly, these signaling pathways are also differentially affected by C-terminal splice variants of bovine prostanoid EP₃ receptors (11), with two isoforms inhibiting and two activating adenylate cyclase. These data are consistent with previous ideas about the role of the i3 loop and C terminus in G protein coupling, and suggest that alternative splicing of GPCRs might be a major mechanism for controlling signaling specificity.

Nevertheless, differences in coupling between splice variants seem to be neither robust nor consistent. For example, human PACAP receptor splice variants differ from their rat orthologs in that distinct human isoforms show similar activation of adenylate cyclase (12). Similarly, all four human EP₃ receptor splice variants inhibit adenylate cyclase (13), whereas a mixture of inhibition and stimulation occurs upon activation of the bovine isoforms. Rat SSTR₂ (somatostatin receptor type 2) C-terminal splice variants do not show the differences in coupling observed with mouse orthologs (14), and the proposed differential coupling of i3 loop variants of the D₂ dopamine receptor to distinct G_i proteins is also controversial (15).

These discrepancies may be due to the difficulties involved in comparing coupling efficiencies of closely related receptors. Heterologous expression is usually required, and the lack of suitable radioligands or antibodies can make it difficult to determine whether similar expression levels are achieved, and whether receptor density is within a physiological range. In fact, in studies where receptor density can be controlled and quantified, splice variants often show few differences in coupling efficiency. For example, human _1A-adrenergic receptor isoforms show comparable activation of phospholipase C (16), and human 5HT₄ receptor isoforms cause similar activation of adenylate cyclase (17). Thus, although coupling efficiency may vary for alternatively spliced GPCRs, these differences are often subtle and their biological significance remains to be determined.

DESENSITIZATION
Phosphorylation of the C-terminal tail is important in the desensitization of many GPCRs; intriguingly, one of the most obvious differences among C-terminal splice variants is in the number of potential phosphorylation sites. For example, the C-terminal tail of the human prostanoid TPß receptor contains an additional eleven serines, an additional four threonines, and one extra tyrosine compared to the shorter TP isoform (18), and the mGluR1a contains fifty-four more Ser/Thr residues than the much shorter mGluR1b (19). For this reason, desensitization patterns of several C-terminal splice variants have been carefully compared.

Despite these dramatic sequence alterations, differences in desensitization of C-terminal splice variants have been found to be relatively modest. The clearest differences appear to be associated with receptor internalization. As shown in Figure 2, rat mu-opioid (20) and human mGluR1 (21) receptor C-terminal splice variants both exhibit differences in agonist-induced internalization. In both cases, chronic agonist exposure causes a greater loss in cell surface localization for the shorter isoform (mu-opioid-1B, mGluR1b) than for the longer isoform. These observations must be interpreted cautiously, however, because loss in receptor density at the cell surface is a function of both internalization and recovery to the membrane, two processes that can vary independently (20). Also, some C-terminal splice variants show no apparent differences in desensitization. Human prostanoid TP and TPß C-terminal isoforms have large differences in the number of potential phosphorylation sites, but a thorough study using isoform-specific antibodies found similar dose- and time-dependence for agonist-induced phosphorylation, and identical rates of desensitization (18). Other studies of the same receptors have, however, reported differences in splice variant internalization (22). Thus, C-terminal splice variants of GPCRs sometimes, although not always, show differences in desensitization.

View larger version (23K): [in this window] [in a new window]   Figure 2. Examples of C-terminal splice variants exhibiting different desensitization profiles. The time course of the effect of agonist exposure on cell surface receptor expression is shown schematically for rat mu-opioid (20) and human mGluR1 (21) receptor isoforms.

LIGAND BINDING
Because intracellular domains do not generally contribute to formation of the ligand-binding pocket, it is not surprising that splice variation of intracellular sequences elicits almost no effect on ligand binding. Pharmacological differences are more likely to be associated with N-terminal splice variants. In fact, an N-terminal splice variant of the PACAP receptor, with a 21-residue deletion, causes a substantial change in agonist affinity (26). Conversely, no significant differences in ligand binding profiles have been reported for N-terminal splice variants of the CRFR2 and GABA_B-R₁ receptors. However, it is difficult to draw broad conclusions because the number of N-terminal splice variants is limited, and there are few drugs available for characterizing these receptors.

	LOCALIZATION

TOP Abstract INTRODUCTION GPCR GENESTRUCTURE AND SPLICE... FUNCTIONAL DIFFERENCES BETWEEN... LOCALIZATION PROTEIN-PROTEIN INTERACTIONS... DIMERIZATION CONCLUSIONS REFERENCES

 
Sequence-specific probes have made it possible to map, by in situ hybridization, the distribution of differentially spliced GPCR mRNA, particularly in brain. Not surprisingly, GPCR splice variants often show differential distribution among many tissues and brain regions (1), consistent with cell-specific control of transcription and splicing. A recent report suggests that different D₂ dopamine receptor isoforms, formed by alternate splicing of the i3 loop, effect distinct functions based on their preferential pre- versus postsynaptic localization. Specifically, the targeted ablation of the additional exon that establishes the D₂ long isoform resulted in mice expressing only the short form of the D₂ receptor but evidencing normal total D₂ receptor density and pharmacology. Significantly, however, D₂-mediated postsynaptic motor responses were essentially abolished in these mice, whereas D₂ presynaptic regulation of dopamine release appeared to be normal (27). Thus, the D₂ long isoform functions primarily postsynaptically, and the D₂ short isoform appears to be primarily presynaptic. Little is known about the mechanisms underlying such differential distribution, which may reveal quite a bit about the functional roles of these splice variants.

	PROTEIN-PROTEIN INTERACTIONS INVOLVING INTRACELLULAR DOMAINS OF GPCRs

TOP Abstract INTRODUCTION GPCR GENESTRUCTURE AND SPLICE... FUNCTIONAL DIFFERENCES BETWEEN... LOCALIZATION PROTEIN-PROTEIN INTERACTIONS... DIMERIZATION CONCLUSIONS REFERENCES

 
It has become clear in recent years that GPCRs exhibit specific interactions with many proteins in addition to G proteins, such as anchoring molecules, molecules involved in intracellular signaling, and "adaptor" molecules that may link receptors to other molecules or signals. Such protein–protein interactions depend mainly upon intracellular domains, particularly on the C-terminal tail (28). Because these are the domains most commonly altered in GPCR splice variants, it is likely that splicing will influence such interactions.

Although GPCRs have been known for many years to bind arrestins and kinases involved in desensitization, the diversity of other proteins that bind to GPCR intracellular domains has only recently become apparent. In this regard, one important protein is Homer, an immediate-early gene product found to associate with the C-terminal tails of mGluRs 1 and 5 (29). Homer represents a family of proteins, the longer forms of which have coiled-coil domains that mediate the formation of multimeric complexes. Homer proteins bind to a C-terminal proline-rich sequence of mGluR1 family members that is also present in both the ryanodine receptor and the inositol 1,4,5-trisphosphate receptor. It has been suggested that Homer proteins create a regulated physical link between mGluR receptors and inositol 1,4,5-trisphosphate receptors, and that this link is disrupted by production of the immediate-early-gene product Homer-1a (30), which lacks the coiled-coil domain.

Significantly, the Homer-binding motif is present in both splice variants of the mGluR5 receptor and in the mGluR1a receptor, but is not present in the three mGluR1b, mGluR1c, or mGluR1d receptor splice variants (31). In these latter three isoforms, the long C-terminal tail (318 residues) of mGluR1a is replaced by a much shorter C-terminal sequence (11-26 residues), eliminating the Homer-binding domain. If the current model is correct, removal of this binding domain will have an important impact on the properties of mGluR1 splice variants, probably leading to alterations in localization, coupling, and regulation.

Another novel protein found to interact with a GPCR intracellular domain is the sodium/hydrogen exchange regulatory factor (NHERF). This PDZ domain–containing protein associates specifically with the last four amino acids of the C terminus of the ß₂-adrenergic receptor in an agonist-dependent manner (32). PDZ domains are important components of molecular scaffolds that hold large multiprotein signaling complexes together, and are thought to correctly position signaling molecules for interaction. Although there are no ß₂-adrenergic receptor splice variants, there may be similar interactions of PDZ domains with other GPCRs. This is particularly interesting because C-terminal splice variants often differ by only a few amino acids at the end of the tail, precisely where PDZ domains bind.

Protein partners that interact with the i3 loop of GPCRs have also been identified (28). An example is spinophilin, which binds to the i3 loop of dopamine D₂ receptors (33), where alternative splicing can occur. Protein–protein interactions may also be important in the function of N-terminal splice variants. The N-terminal domain of the GABA_B-R₁ receptor contains two complement protein modules (SCR or "sushi" domains) that are involved in specific protein–protein recognition events. Either one or both of these modules are removed in the two known human GABA_B-R₁ splice variants (35, 36). The functional significance of this splice variation has yet to be determined.

These observations suggest that important functional differences between splice variants may be explained by the presence or absence of protein-binding motifs and resulting differences in protein–protein interactions. Differential interactions of such proteins with GPCR splice variants could have a marked impact on their localization and/or functional properties, as illustrated schematically in Figure 3. In fact, C-terminal binding partners for SSTR₂ (SSTRIP/Shank1) (37), mGluR7 (calmodulin) (38), and _1A-adrenergic receptors (neuronal nitric oxide synthase) (39) have been reported. All of these receptors exist as C-terminal splice variants, although we do not yet know whether the partner proteins will bind differentially to these splice variants and the functional significance of such interactions remains unclear. However, the identification of such binding partners strengthens the hypothesis that alternate splicing of GPCRs may remove or add particular protein-binding motifs, resulting in receptors with differential localization and function.

View larger version (36K): [in this window] [in a new window]   Figure 3. Potential role of protein–protein interactions in the differentiation of splice variant function. C-terminal splice variation may result in distinct protein-binding motifs, leading to specific interactions with intracellular proteins. This mode of functional regulation, mediated by splicing, is shown in the schematic for two variants of mGluR1. Specifically, the immediate-early gene product Homer is schematized to interact with mGluR1a but not the shorter C-terminal splice variant mGluR1b. Homer proteins bind to a proline-rich consensus motif in the C-terminal tail of mGluR1a that is spliced out of mGluR1b. The homodimerization of Homer through its coiled-coil domains is proposed to physically link the mGluR1a receptor to the inositol 1,4,5-trisphosphate receptor (IP3R), which also contains a Homer binding motif. Because the mGluR1b (shown), mGluR1c, and mGluR1d C-terminal splice variants do not contain a Homer binding motif, they would not be expected to associate with Homer proteins. Whether these C-terminal splice variants specifically interact with other proteins is not yet known. Other protein-binding sequences that may be introduced into or excluded from GPCRs are discussed in the text.

	DIMERIZATION

TOP Abstract INTRODUCTION GPCR GENESTRUCTURE AND SPLICE... FUNCTIONAL DIFFERENCES BETWEEN... LOCALIZATION PROTEIN-PROTEIN INTERACTIONS... DIMERIZATION CONCLUSIONS REFERENCES

	CONCLUSIONS

TOP Abstract INTRODUCTION GPCR GENESTRUCTURE AND SPLICE... FUNCTIONAL DIFFERENCES BETWEEN... LOCALIZATION PROTEIN-PROTEIN INTERACTIONS... DIMERIZATION CONCLUSIONS REFERENCES

 
It is now clear that a relatively small subset of GPCRs undergo alternative splicing to generate isoforms differing in particular intracellular and extracellular domains. Most of the verified human splice variants represent variation of GPCR C termini, although splicing can also affect other regions. We still know little about the functional roles of GPCR splice variants, but differences in ligand binding, signaling efficiency, constitutive activity, and desensitization have been reported. This area has recently become more interesting not only by the discovery of a large number of intracellular proteins that specifically associate with GPCRs, but also by the recognition that some GPCRs require heterodimerization for correct assembly and function. Because these protein–protein interactions often involve C-terminal domains, splice variants may arise as a mechanism to regulate such associations. The addition or deletion of discrete protein binding motifs by alternative splicing may thus confer important functional characteristics on particular splice variants, and the elucidation of such characteristics may provide new insights into the physiological function of GPCR splice variation.

Kenneth P. Minneman, Ph.D., is Charles Howard Candler Professor of Pharmacology at Emory University. His research interests include the pharmacology, structure, molecular biology, and mechanisms of signal transduction of adrenergic receptor subtypes.

	REFERENCES

TOP Abstract INTRODUCTION GPCR GENESTRUCTURE AND SPLICE... FUNCTIONAL DIFFERENCES BETWEEN... LOCALIZATION PROTEIN-PROTEIN INTERACTIONS... DIMERIZATION CONCLUSIONS REFERENCES

 

1. Kilpatrick, G.J., Dautzenberg, F.M., Martin, G.R., and Eglen, R.M. 7TM receptors: The splicing on the cake. Trends Pharmacol. Sc.i 20, 294–301 (1999).[Medline]
2. Gentles, A.J. and Karlin, S. Why are human G-protein-coupled receptors predominantly intronless? Trends Genet. 15, 47–49 (1999).[Medline]
3. Monsma, F.J., Jr., McVittie, L.D., Gerfen, C.R., Mahan, L.C., and Sibley, D.R. Multiple D2 dopamine receptors produced by alternative RNA splicing. Nature 342,926 –929 (1989).[Medline]
4. Saudou, F., Boschert, U., Amlaiky, N., Plassat, J.L., and Hen, R.A family of Drosophila serotonin receptors with distinct intracellular signalling properties and expression patterns. EMBO J. 11,7 –17 (1992).[Medline]
5. Kroeze, W.K. and Roth, B.L. The molecular biology of serotonin receptors: therapeutic implications for the interface of mood and psychosis. Biol. Psychiatry 44, 1128–1142 (1998).[Medline]
6. Park, Y.S., Lee, Y.S., Cho, N.J., and Kaang, B.K. Alternative splicing of gar-1, a Caenorhabditis elegans G-protein-linked acetylcholine receptor gene. Biochem. Biophys. Res. Commun. 268,354 –358 (2000).[Medline]
7. Zhong, H. and Minneman, K.P. Alpha1-adrenoceptor subtypes. Eur. J. Pharmacol. 375,261 –276 (1999).[Medline]
8. Hirasawa, A., Shibata, K., Horie, K., Takei, Y, Obika, K., Tanaka, T., Muramoto, N., Takagaki, K., Yano, J., and Tsujimoto, G. Cloning, functional expression and tissue distribution of human alpha 1c-adrenoceptor splice variants. FEBS Lett. 363, 256–260 (1995).[Medline]
9. Chang, D.J., Chang, T.K., Yamanishi, S.S., Salazar, F.H., Kosaka, A.H., Khare, R., Bhakta, S., Jasper, J.R., Shieh, I.S., Lesnick, J.D., Ford, A.P., Daniels, D.V., Eglen, R.M., Clarke, D.E., Bach, C., and Chan, H.W. Molecular cloning, genomic characterization and expression of novel human alpha1A-adrenoceptor isoforms. FEBS Lett. 422, 279–283 (1998).[Medline]
10. Spengler, D., Waeber, C., Pantaloni, C., Holsboer, F., Bockaert, J., Seeburg, P.H., and L. Journot. Differential signal transduction by five splice variants of the PACAP receptor. Nature 365,170 –175 (1993).[Medline]
11. Namba, T., Sugimoto, Y., Negishi, M., Irie, A., Ushikubi, F., Kakizuka, A., Ito, S., Ichikawa. A., and Narumiya, S. Alternative splicing of C-terminal tail of prostaglandin E receptor subtype EP3 determines G-protein specificity. Nature 365, 166–170 (1993).[Medline]
12. Pisegna, J.R. and Wank, S.A. Cloning and characterization of the signal transduction of four splice variants of the human pituitary adenylate cyclase activating polypeptide receptor. Evidence for dual coupling to adenylate cyclase and phospholipase C. J. Biol. Chem. 271,17267 –17274 (1996).[Abstract/Free Full Text]
13. Kotani, M., Tanaka, I., Ogawa, Y., Usui, T., Mori, K., Ichikawa, A., Narumiya, S., Yoshimi, T., and Nakao, K. Molecular cloning and expression of multiple isoforms of human prostaglandin E receptor EP3 subtype generated by alternative messenger RNA splicing: multiple second messenger systems and tissue-specific distributions. Mol. Pharmacol. 48, 869–879 (1995).[Abstract]
14. Schindler, M., Kidd, E.J., Carruthers, A.M., Wyatt, M.A., Jarvie, E.M., Sellers, L.A., Feniuk, W. and Humphrey, P.P. Molecular cloning and functional characterization of a rat somatostatin sst2(b) receptor splice variant. Br. J. Pharmacol. 125, 209–217 (1998).[Medline]
15. Missale, C., Nash, S.R., Robinson, S.W., Jaber, M., and Caron, M.G. Dopamine receptors: From structure to function. Physiol. Rev. 78, 189–225 (1998).[Abstract/Free Full Text]
16. Daniels, D. V., Gever, J.R., Jasper, J.R., Kava, M.S., Lesnick, J.D., Meloy, T.D., Stepan, G., Williams, T.J., Clarke, D.E., Chang, D.J., and Ford, A.P. Human cloned alpha1A-adrenoceptor isoforms display alpha1L-adrenoceptor pharmacology in functional studies. Eur. J. Pharmacol. 370,337 –343 (1999).[Medline]
17. Blondel, O., Gastineau, M., Dahmoune, Y., Langlois, M., and Fischmeister, R. Cloning, expression, and pharmacology of four human 5-hydroxytryptamine 4 receptor isoforms produced by alternative splicing in the carboxyl terminus. J. Neurochem. 70, 2252–2261 (1998).[Medline]
18. Habib, A., Vezza, R., Creminon, C., Maclouf, J., and FitzGerald, G.A. Rapid, agonist-dependent phosphorylation in vivo of human thromboxane receptor isoforms. Minimal involvement of protein kinase C. J. Biol. Chem. 272, 7191–7200 (1997).[Abstract/Free Full Text]
19. Conn, P. J. and Pin, J.P. Pharmacology and functions of metabotropic glutamate receptors. Annu. Rev. Pharmacol. Toxicol. 37, 205–237 (1997).[Medline]
20. Koch, T., Schulz, S., Schroder, H., Wolf, R., Raulf, E., and Hollt, V. Carboxyl-terminal splicing of the rat mu opioid receptor modulates agonist-mediated internalization and receptor resensitization. J. Biol. Chem. 273, 13652–13657 (1998).[Abstract/Free Full Text]
21. Ciruela, F. and McIlhinney, R.A. Differential internalisation of mGluR1 splice variants in response to agonist and phorbol esters in permanently transfected BHK cells. FEBS Lett. 418,83 –86 (1997).[Medline]
22. Parent, L.C., Labreque, P., Orsini, M.J., and Benovic, J.L. Internalization of the TXA2 receptor and ß forms. J. Biol. Chem. 274, 8941–8948 (1999).[Abstract/Free Full Text]
23. Prezeau, L., Gomeza, J., Ahern, S., Mary, S., Galvez, T., Bockaert, J., and Pin, J.P. Changes in the carboxyl-terminal domain of metabotropic glutamate receptor 1 by alternative splicing generate receptors with differing agonist-independent activity. Mol. Pharmacol. 49,422 –429 (1996).[Abstract]
24. Jin, J., Mao, G.F., and Ashby, B. Constitutive activity of human prostaglandin E receptor EP3 isoforms. Br. J. Pharmacol. 121, 317–323 (1997).[Medline]
25. Claeysen, S., Sebben, J., Becamel, C., Bockaert, J., and Dumuis, A. Novel brain-specific 5-HT4 receptor splice variants show marked constitutive activity: Role of the C-terminal intracellular domain. Mol. Pharmacol. 55, 910–920 (1999).[Abstract/Free Full Text]
26. Pantaloni, C., Brabet, P., Bilanges, B., Dumuis, A., Houssami, S., Spengler, D., Bockaert, J., and Journot, L. Alternative splicing in the N-terminal extracellular domain of the pituitary adenylate cyclase-activating polypeptide (PACAP) receptor modulates receptor selectivity and relative potencies of PACAP-27 and PACAP-38 in phospholipase C activation. J. Biol. Chem. 271,22146 –22151 (1996).[Abstract/Free Full Text]
27. Usiello, A., Baik, J.H., Rouge-Pont, F., Picetti, R., Dierich, A., LeMeur, M., Piazza, P.V., and Borrelli, E. Distinct functions of the two isoforms of dopamine D2 receptors. Nature 408,199 –203 (2000).[Medline]
28. Heuss, C. and Gerber, U. G-protein-independent signaling by G-protein-coupled receptors. Trends in Neuroscience 23, 469–475 (2000).[Medline]
29. Brakeman, P. R., Lanahan, A.A., Roche, K., Barnes, C.A., Huganir, R.L., and Worley, P.F. Homer: A protein that selectively binds metabotropic glutamate receptors. Nature 386,284 –288 (1997).[Medline]
30. Xiao, B., J. Tu, C., Petralia, R.S., Yuan, J.P., Doan, A., Breder, C.D., Ruggiero, A., Lanahan, A.A., Wenthold, R.J., and Worley, P.F. Homer regulates the association of group 1 metabotropic glutamate receptors with multivalent complexes of Homer-related, synaptic proteins. Neuron 21,707 –716 (1998).[Medline]
31. Fagni, L., Chavis, P., Ango, F., and Bockaert, J. Complex interactions between mGluRs, intracellular Ca2+ stores and ion channels in neurons. Trends in Neuroscience 23, 80–8 (2000).[Medline]
32. Hall, R. A., Premont, R.T., Chow, C.W., Blitzer, J.T., Pitcher, J.A., Claing, A., Stoffel, R.H., Barak, L.S, Shenolikar, S., Weinman, E.J., Grinstein, S., and Lefkowitz, R.J. The beta2-adrenergic receptor interacts with the Na+/H+-exchanger regulatory factor to control Na+/H+ exchange. Nature 392,626 –630 (1998).[Medline]
33. Smith, F. D., Oxford, G.S., and Milgram, S.L. Association of the D2 dopamine receptor third cytoplasmic loop with spinophilin, a protein phosphatase-1-interacting protein. J. Biol. Chem. 274,19894 –19900 (1999).[Abstract/Free Full Text]
34. Hawrot, E., Xiao, Y., Shi, Q.L., Norman, D, Kirkitadze, M., and Barlow, P.N. Demonstration of a tandem pair of complement protein modules in GABA(B) receptor 1a. FEBS Lett. 432,103 –108 (1998).[Medline]
35. White, J. H., Wise, A., Main, M.J., Green, A., Fraser, N.J., Disney, G.H., Barnes, A.A., Emson, P., Foord, S.M., and Marshall, F.H. Heterodimerization is required for the formation of a functional GABA(B) receptor. Nature 396, 679–682 (1998).[Medline]
36. Calver, A. R., Medhurst, A.D., Robbins, M.J., Charles, K.J., Evans, M.L., Harrison, D.C., Stammers, M., Hughes, S.A., Hervieu, G., Couve, A., Moss, S.J., Middlemiss, D.N., and Pangalos, M.N. The expression of GABA(B1) and GABA(B2) receptor subunits in the cNS differs from that in peripheral tissues Neuroscience 100, 155–170 (2000).[Medline]
37. Zitzer, H., Honck, H.H., Bachner, D., Richter, D., and Kreienkamp, H.J. Somatostatin receptor interacting protein defines a novel family of multidomain proteins present in human and rodent brain. J. Biol. Chem. 274,32997 –33001 (1999).[Abstract/Free Full Text]
38. O'Connor, V., El Far, O., Bofill-Cardona, E., Nanoff, C., Freissmuth, M., Karschin, A., Airas, J.M., Betz, H., and Boehm, S. Calmodulin dependence of presynaptic metabotropic glutamate receptor signaling. Science 286, 1180–1184 (1999).[Abstract/Free Full Text]
39. Schepens, J., Cuppen, E., Wieringa, B., and Hendriks, W. The neuronal nitric oxide synthase PDZ motif binds to -G(D,E)XV* carboxyterminal sequences. FEBS Lett. 409,53 –56 (1997).[Medline]
40. Margeta-Mitrovic, M., Jan, Y.N., and Jan, L.Y. A trafficking checkpoint controls GABA(B) receptor heterodimerization. Neuron 27, 97–106 (2000).[Medline]
41. Jordan, B. A., Cvejic, S., and Devi, L.A. Opioids and their complicated receptor complexes. Neuropsychopharmacology 23, S5–S18 (2000).[Medline]

This article has been cited by other articles:

				C. Y. Wang, Y. Wang, A. H. Y. Kwok, and F. C Leung Identification of two novel chicken GHRH receptor splice variants: implications for the roles of aspartate 56 in the receptor activation and direct ligand receptor interaction J. Endocrinol., December 1, 2007; 195(3): 525 - 536. [Abstract] [Full Text] [PDF]

				N. Hatae, N. Aksentijevich, H. W. Zemkova, K. Kretschmannova, M. Tomic, and S. S. Stojilkovic Cloning and Functional Identification of Novel Endothelin Receptor Type A Isoforms in Pituitary Mol. Endocrinol., May 1, 2007; 21(5): 1192 - 1204. [Abstract] [Full Text] [PDF]

				J. Grosse, P. Tarnow, H. Rompler, B. Schneider, R. Sedlmeier, U. Huffstadt, D. Korthaus, M. Nehls, S. Wattler, T. Schoneberg, et al. N-ethyl-N-nitrosourea-based generation of mouse models for mutant G protein-coupled receptors Physiol Genomics, September 14, 2006; 26(3): 209 - 217. [Abstract] [Full Text] [PDF]

				P. Wang, B. Yan, J.-t. Guo, C. Hicks, and Y. Xu Structural genomics analysis of alternative splicing and application to isoform structure modeling PNAS, December 27, 2005; 102(52): 18920 - 18925. [Abstract] [Full Text] [PDF]

				A. Perron, P. Sarret, L. Gendron, T. Stroh, and A. Beaudet Identification and Functional Characterization of a 5-Transmembrane Domain Variant Isoform of the NTS2 Neurotensin Receptor in Rat Central Nervous System J. Biol. Chem., March 18, 2005; 280(11): 10219 - 10227. [Abstract] [Full Text] [PDF]

This Article Summary Full Text (PDF) Expanded Tables Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Minneman, K. P. Search for Related Content PubMed PubMed Citation Articles by Minneman, K. P.